{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:13:58Z","timestamp":1793830438896,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s40618-018-0984-z","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T09:12:36Z","timestamp":1542964356000},"page":"745-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)"],"prefix":"10.1007","volume":"42","author":[{"given":"R. M.","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Campenn\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Trimboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Giovanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"984_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/cbr.2010.0902","volume":"26","author":"RO Dillman","year":"2011","unstructured":"Dillman RO (2011) Cancer immunotherapy. Cancer Biother Radiopharm 26:1\u201364","journal-title":"Cancer Biother Radiopharm"},{"key":"984_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10555-011-9280-5","volume":"30","author":"TJ Stewart","year":"2011","unstructured":"Stewart TJ, Smyth MJ (2011) Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metast Rev 30:125\u2013140","journal-title":"Cancer Metast Rev"},{"key":"984_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","volume":"121","author":"R Kim","year":"2007","unstructured":"Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1\u201314","journal-title":"Immunology"},{"key":"984_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Intern Immunol 8:765\u2013772","journal-title":"Intern Immunol"},{"key":"984_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-3083.2001.00985.x","volume":"54","author":"XB Wang","year":"2001","unstructured":"Wang XB, Zheng CY, Giscombe R, Lefvert AK (2001) Regulation of surface and intracellular expression of CTLA4 oh human peripheral T cells. Scand J Immunol 54:453\u2013458","journal-title":"Scand J Immunol"},{"key":"984_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974\u20131982","journal-title":"J Clin Oncol"},{"key":"984_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"key":"984_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Society for Immunotherapy of Cancer Toxicity Management Working Group et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. \n                    https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"984_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow M, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21:371\u2013381","journal-title":"Endocr Relat Cancer"},{"key":"984_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190\u2013209","journal-title":"Eur J Cancer"},{"key":"984_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM et al (2016) Prolonged survival in stage III Melanoma with Ipilimumab adjuvant therapy. N Engl J Med 375:1845\u20131855","journal-title":"N Engl J Med"},{"key":"984_CR12","unstructured":"US Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda, Md, 2010. [updated (v4.03: June 14, 2010) May 28, 2009]. NIH publication no. 90-5410"},{"key":"984_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"984_CR14","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D\u2019Angelo SP, Woo KM et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193\u20133198","journal-title":"J Clin Oncol"},{"key":"984_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550","journal-title":"Lancet"},{"key":"984_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"984_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/L18-0209","volume":"169","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and pre-existing autoimmune disease. Ann Intern Med 169:133\u2013134. \n                    https:\/\/doi.org\/10.7326\/L18-0209","journal-title":"Ann Intern Med"},{"key":"984_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Gr\u00fcnwald V, K\u00e4hler KC, Loquai C, Reinmuth N, Steins M et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD1 antibody therapy. Cancer Treat Rev 45:7\u201318","journal-title":"Cancer Treat Rev"},{"key":"984_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","volume":"85","author":"MN Joshi","year":"2016","unstructured":"Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV (2016) Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction. Clin Endocrinol 85:331\u2013339","journal-title":"Clin Endocrinol"},{"key":"984_CR20","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"JS Weber","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebb\u00e9 C, Hodi FS, MDX010-20 Investigators (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:1675\u20131682","journal-title":"Cancer"},{"key":"984_CR21","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2354\u20132443","journal-title":"N Engl J Med"},{"key":"984_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","volume":"41","author":"F Guaraldi","year":"2018","unstructured":"Guaraldi F, La Selva R, Sam\u00e0 MT, D\u2019Angelo V, Gori D, Fava P, Fierro MT, Savoia P, Arvat E (2018) Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 41:549\u2013556. \n                    https:\/\/doi.org\/10.1007\/s40618-017-0772-1","journal-title":"J Endocrinol Invest"},{"key":"984_CR23","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L et al (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078\u20134085","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","volume":"38","author":"PB Araujo","year":"2015","unstructured":"Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV (2015) Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38:1159\u20131166. \n                    https:\/\/doi.org\/10.1007\/s40618-015-0301-z","journal-title":"J Endocrinol Invest"},{"key":"984_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side-effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:1361\u20131375","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s12020-014-0199-9","volume":"47","author":"J Marlier","year":"2014","unstructured":"Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V (2014) Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine 47:878\u2013883","journal-title":"Endocrine"},{"key":"984_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","volume":"13","author":"T Dillard","year":"2010","unstructured":"Dillard T, Yedinak CG, Alumkal J, Fleseriu M (2010) Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13:29\u201338","journal-title":"Pituitary"},{"key":"984_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","volume":"28","author":"JA Blansfield","year":"2005","unstructured":"Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C et al (2005) Cytotoxic T lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593\u2013598","journal-title":"J Immunother"},{"key":"984_CR29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3174\/ajnr.A1623","volume":"30","author":"KJ Carpenter","year":"2009","unstructured":"Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR (2009) Ipilimumab-induced hypophysitis: MR imaging findings. Am J Neuroradiol 30:1751\u20131753","journal-title":"Am J Neuroradiol"},{"key":"984_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","volume":"41","author":"P Chalan","year":"2018","unstructured":"Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P (2018) Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest 41:625\u2013638. \n                    https:\/\/doi.org\/10.1007\/s40618-017-0778-8","journal-title":"J Endocrinol Invest"},{"key":"984_CR31","first-page":"372(26)","volume":"19","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 19:372(26)","journal-title":"N Engl J Med"},{"key":"984_CR32","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4158\/EP171832.OR","volume":"23","author":"G O\u2019Malley","year":"2017","unstructured":"O\u2019Malley G, Lee HJ, Parekh S, Galsky MD, Smith CB, Friedlander P, Yanagisawa RT, Gallagher EJ (2017) Rapid evolution of thyroid dysfunction in patients treated with nivolumab. Endocr Pract 23:1223\u20131231","journal-title":"Endocr Pract"},{"key":"984_CR33","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1210\/jc.2014-4560","volume":"100","author":"S Orlov","year":"2015","unstructured":"Orlov S, Salari F, Kashat L, Walfish PG (2015) Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 100:1738\u20131741","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","volume":"27","author":"I Yamauchi","year":"2017","unstructured":"Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y et al (2017) Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid 27:894\u2013901","journal-title":"Thyroid"},{"issue":"2","key":"984_CR35","doi-asserted-by":"publisher","first-page":"A2 (1\u20136)","DOI":"10.6092\/1828-6550\/apmb.105.2.2017.a2","volume":"105","author":"G Giuffrida","year":"2017","unstructured":"Giuffrida G, Campenn\u00ec A, Trimarchi F, Ruggeri RM (2017) Thyroid dysfunction in patients treated with the immune checkpoint inhibitor nivolumab: different clinical features. APMB 105(2):A2 (1\u20136). \n                    https:\/\/doi.org\/10.6092\/1828-6550\/apmb.105.2.2017.a2","journal-title":"APMB"},{"key":"984_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/EJE-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303\u2013307","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"984_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40618-018-0906-0","volume":"41","author":"E Sabini","year":"2018","unstructured":"Sabini E, Sframeli A, Marin\u00f2 M (2018) A case of drug-induced Graves\u2019 orbitopathy after combination therapy with Tremelimumab and Durvalumab. J Endocrinol Invest 41(7):877\u2013878. \n                    https:\/\/doi.org\/10.1007\/s40618-018-0906-0\n                    \n                  \n                           (Epub 26 May 2018)","journal-title":"J Endocrinol Invest"},{"key":"984_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13104-015-1283-9","volume":"8","author":"D Carl","year":"2015","unstructured":"Carl D, Grullich C, Hering S, Schabet M (2015) Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Res Notes 8:316","journal-title":"BMC Res Notes"},{"key":"984_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-214603","author":"B McMillen","year":"2016","unstructured":"McMillen B, Dhillon, Yong-Yow S (2016) A rare case of thyroid storm. BMJ Case Rep. \n                    https:\/\/doi.org\/10.1136\/bcr-2016-214603","journal-title":"BMJ Case Rep"},{"key":"984_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","volume":"5","author":"U Khan","year":"2017","unstructured":"Khan U, Rizvi H, Sano D, Chiu J, Hadid T (2017) Nivolumab induced myxedema crisis. J Immunother Cancer 5:13","journal-title":"J Immunother Cancer"},{"key":"984_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(13)70031-7","volume":"1","author":"L Min","year":"2013","unstructured":"Min L, Ibrahim N (2013) Ipilimumab-induced autoimmune andrenalitis. Lancet Diabetes Endocrinol 1:15","journal-title":"Lancet Diabetes Endocrinol"},{"key":"984_CR42","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-13-1020","volume":"170","author":"G Spasovski","year":"2014","unstructured":"Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E, Hyponatraemia Guideline Development Group (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 170:G1\u201347. \n                    https:\/\/doi.org\/10.1530\/EJE-13-1020","journal-title":"Eur J Endocrinol"},{"key":"984_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2214\/AJR.15.15480","volume":"207","author":"SA Howard","year":"2016","unstructured":"Howard SA, Krajewski KM, Jagannathan JP, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, Ramaiya NH (2016) A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy. Am J Roentgenol 207:4\u201314. \n                    https:\/\/doi.org\/10.2214\/AJR.15.15480","journal-title":"Am J Roentgenol"},{"issue":"11","key":"984_CR44","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","volume":"40","author":"S Bacanovic","year":"2015","unstructured":"Bacanovic S, Burger IA, Stolzmann P, Hafner J, Huellner MW (2015) Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT. Clin Nucl Med 40(11):e518\u2013e519. \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000000887","journal-title":"Clin Nucl Med"},{"key":"984_CR45","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.2337\/dc15-0889","volume":"38","author":"M Mellati","year":"2015","unstructured":"Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, Hirsch IB (2015) Anti-PD-1 and Anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care 38:e137\u2013e138. \n                    https:\/\/doi.org\/10.2337\/dc15-0889","journal-title":"Diabetes Care"},{"key":"984_CR46","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.2337\/dc15-1331","volume":"38","author":"C Gaudy","year":"2015","unstructured":"Gaudy C, Cl\u00e9vy C, Monestier S, Dubois N, Pr\u00e9au Y, Mallet S, Richard MA, Grob JJ, Val\u00e9ro R, B\u00e9liard S (2015) Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 38:e182\u2013e183. \n                    https:\/\/doi.org\/10.2337\/dc15-1331","journal-title":"Diabetes Care"},{"key":"984_CR47","doi-asserted-by":"publisher","first-page":"93280","DOI":"10.1371\/journal.pone.0093280","volume":"9","author":"C Cochain","year":"2014","unstructured":"Cochain C, Chaudhari SM, Koch M, Wiendl H, Eckstein HH, Zernecke A (2014) Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS One 9:93280","journal-title":"PLoS One"},{"key":"984_CR48","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","volume":"31","author":"DX Bu","year":"2011","unstructured":"Bu DX, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH (2011) Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 31:1100\u20131107","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"984_CR49","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1080\/2162402X.2016.1204507","volume":"5","author":"H Inoue","year":"2016","unstructured":"Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y et al (2016) Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 5:1204\u20131507","journal-title":"Oncoimmunology"},{"key":"984_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1479-5876-11-75","volume":"11","author":"V Shahabi","year":"2013","unstructured":"Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, Panting L, Jure-Kunkel M, Ji RR (2013) Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune- related gastrointestinal adverse events. J Transl Med 11:75","journal-title":"J Transl Med"},{"key":"984_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"172","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, Carr\u00e9 T, Morange I, Conte-Devolx B, Grob JJ, Brue T (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172:195\u2013204","journal-title":"Eur J Endocrinol"},{"key":"984_CR52","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EC-18-0068","volume":"7","author":"CE Higham","year":"2018","unstructured":"Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, Morganstein D, Trainer PJ, Society for Endocrinology Clinical Committee (2018) Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7:G1\u2013G7. \n                    https:\/\/doi.org\/10.1530\/ec-18-0068","journal-title":"Endocr Connect"},{"key":"984_CR53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","volume":"21","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB (2015) Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21:749\u2013755","journal-title":"Clin Cancer Res"},{"key":"984_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fphar.2017.00311","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar V, Chaundary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:311. \n                    https:\/\/doi.org\/10.3389\/fphar.2017.00311","journal-title":"Front Pharmacol"},{"key":"984_CR55","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, Guidelines Committee ESMO (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119\u2013iv142. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0984-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0984-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0984-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:17:53Z","timestamp":1574468273000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0984-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0984-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"1 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}